RET and medullary thyroid gland carcinoma: Notably, identification of different RET pathogenic variants improved understanding of the natural course of disease, allowing predictive diagnosis, prophylactic thyroidectomy in pathogenic variants carriers, and targeted therapy with selective RET inhibitors (i.e., selpercatinib and pralsetinib) in advanced or progressive RET-mutant MTC (Table 1).